Clinical Trial Search

Primary: Change in Radiographic Volume of Thyroid Nodule From Baseline at 3, 6 and 12 Months After Laser Ablation — 63.4; 71.087 percentage of volume reduction

Primary: Stiffness of Thyroid Nodules as Measured by Elastography — 2.7; 3.8; 2.7 meters/second

Primary: Treatment Choice — 54; 51; 6; 7 Participants — p=0.720

Primary: Percent Change in Area of Thyroid Nodules — -19.98; -9.31 percentage change — p=0.047

Primary: Shear-Wave Elastography (SWE) Values in kiloPascals (kPa) — 17.50; 31.03; 23.64; 32.14 kPa

Primary: Swallowing Quality of Life — 84.6; 92.3; 81.2; 87.1 units on a scale — p=0.0007

Primary: Primary Efficacy Parameters of Sensitivity of High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles (LSN MRI) — 85.5 percentage…

Primary: Percentage of Participants With Transient Hypoparathyroidism, as Defined by a Day 1 Serum Parathyroid Hormone (PTH) Level of < 10 pg/ml — 24.1; 33.3 percentage of…

Primary: Qualitative Analysis of the Patient and Clinician Experience Using the Conversation Aid — 12; 0; 12; 0 Participants

Primary: Percent Change of Bone Mineral Density in Lumbar and Hip — 3.0; 3.2; 3.8; 5.1 percentage change

Primary: Number of Persons That Are Vitamin D Deficient in the Thyroid Nodule, Thyroid Cancer in Remission, and the Active Thyroid Cancer Groups. — 23; 20; 11 participants…

Primary: Best Overall Response Rate — 9.4; 0; 30 percentage of participants

Primary: Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation — 329; 175 Days — p=<0.0001

Primary: PET-CT Fusion Scanning Sensitivity — 49; 54 percentage of participants

Primary: The Rate of Successful Thyroid Ablation as Defined by Negative Recombinant Human Thyrotropin (rhTSH) Stimulated Radioiodine Whole Body Scan (RAI WBS) at 1 Year. — 10; 10…

Primary: Proportion of Eligible Patients for Feasibility — 213; 318 Participants

Primary: Diagnostic Accuracy — 94; 81 Participants — p=0.003

Primary: Changes in Thyroid Nodule Size — 0.241361; 0.954909; 0.422121; 0.104143 mL

Primary: The Negative Predictive Value (PVV) of MRI

Primary: Time to Tumor Progression — 334; 176 days

Primary: Intellectual Function of Children at 5 Years of Age in Women Diagnosed With a) Subclinical Hypothyroidism or b) Hypothyroxinemia During the First Half of Pregnancy, or…

Primary: Subjects With Transient Hypoparathyroidism. — 10; 14 Participants

Primary: Modified City of Hope Quality of Life Questionnaire for Patients With Thyroid Disease — -36.33 score on a scale

Primary: Thyroid Difficulty Scale Score — 9.8; 9.75 score on a scale

Primary: Tumor Response Rate to LBH589. — 13; 0 participants

Primary: Percentage of Participants With Local-regional Progression-free Survival — 15.2 percentage of all participants

Primary: Change in Tumor Size — 4.7 cm

Primary: The Average Number of Parathyroid Glands Identified (Experimental Group: Glands Identified With Naked Eye + NIRAF; Control Group: Glands Identified With Naked Eye) Per…

Primary: Progression-Free Survival (PFS) — 10.0; 5.7 months — p=0.080

Primary: Assessment of TachoSil® by the Surgeon With Respect to Handling, Utility and Satisfaction in the Operation, Documented Using 10 Point Numerical Rating Scales — 2.54…